Loading...
Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF
BACKGROUND: Sodium–glucose linked transporter type 2 (SGLT-2) inhibition has been shown to reduce cardiovascular mortality in heart failure independently of glycemic control and prevents the onset of atrial arrhythmias, a common co-morbidity in heart failure with preserved ejection fraction (HFpEF)....
Na minha lista:
| Udgivet i: | Cardiovasc Diabetol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7792219/ https://ncbi.nlm.nih.gov/pubmed/33413413 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-020-01208-z |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|